The present invention also provides the method that is used to treat or prevent people's invasive tumor obstacle in yet another aspect.These class methods comprise that not too having the lower dosage of dosage regimen that aggressive or Non-Invasive tumor obstacle use or select with being compared to of selecting uses coenzyme Q10 to the people, thereby treat or prevent the invasive tumor obstacle.In some embodiment, said invasive tumor obstacle comprises cancer of pancreas, hepatocarcinoma, Ewing sarcoma, metastatic breast cancer, metastatic melanoma, the brain cancer (astrocytoma, glioblastoma multiforme), neuroendocrine carcinoma, colon cancer, pulmonary carcinoma, osteosarcoma, androgen independent prostate cancer, ovarian cancer and non_hodgkin lymphoma.In related fields
Moreover, suppression of the mTOR-p70S6K axis is able to induce possessing of unique metabolic features, distinguished by high glucose uptake, incremental lactate production, and low mitochondrial respiration, in TNBC cells ( Estrogen Receptor More than two-thirds of the breast cancer cases present as ER-positive, and cancers with ER-positive without HER2-positive is termed as luminal breast cancer (204)
BMSCs promote the differentiation of NSCs into oligodendrocytes via mediating Id2 and Olig expression through BMP/Smad signaling pathway
N.E.L.B
